Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.6 pts more than Nifty Microcap 250 and 7.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Limited reported unaudited results for Q1 FY2026 (quarter ended June 30, 2025). Revenue from operations rose 19.3% year-on-year to ₹33,874 lakhs, up from ₹28,388 lakhs in Q1 FY2025. Net profit jumped to ₹6,618 lakhs from ₹1,678 lakhs, though the prior-year figure was weighed down by a one-time exceptional charge of ₹2,019 lakhs tied to the discontinuation and sale of the Goa injection plant. On a like-for-like (pre-exceptional) basis, profit before tax also grew sharply from ₹4,302 lakhs to ₹8,881 lakhs, indicating strong underlying growth. Basic and diluted EPS for the quarter stood at ₹39.87 versus ₹10.11 a year ago. Statutory auditor Haribhakti & Co. LLP issued an unmodified limited review report. The company also noted that FY 2024-25 was a transitional 9-month period following the shift in financial year-end from June 30 to March 31.
The headline profit surge is partly flattered by a low base from prior-year exceptional costs, but underlying operating performance shows robust top-line growth and significant margin expansion — a positive signal for shareholders and likely supportive of the stock.